Posted by Michael Wonder on 08 Jan 2021
Inversago Pharma receives rare paediatric disease designation from the FDA for INV-101 for the treatment of Prader-Willi syndrome
7 January 2021 - Inversago Pharma today announced the U.S. FDA granted a rare paediatric disease designation to the Company’s lead compound, INV-101, for the treatment of Prader-Willi syndrome.
A Phase I study with INV-101 is currently on-going to evaluate its safety, tolerability and pharmacokinetics profile.
